Pregled bibliografske jedinice broj: 542689
Dijagnostičko-terapijski pristup u bolesnika s esencijalnom trombocitemijom - Smjernice Hrvatske kooperativne grupe za hematološke bolesti – KROHEM
Dijagnostičko-terapijski pristup u bolesnika s esencijalnom trombocitemijom - Smjernice Hrvatske kooperativne grupe za hematološke bolesti – KROHEM // Liječnički Vjesnik, 132 (2010), 11-12; 333-339 (podatak o recenziji nije dostupan, članak, stručni)
CROSBI ID: 542689 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Dijagnostičko-terapijski pristup u bolesnika s esencijalnom trombocitemijom - Smjernice Hrvatske kooperativne grupe za hematološke bolesti – KROHEM
(Diagnostic and therapeutic approach to patients with essential thrombocythaemia-Guidelines of Croatian Hematology cooperative group-KROHEM)
Autori
Labar, Boris ; Kušec, Rajko ; Jakšić, Branimir ; Škare-Librenjak, Ljubica ; Načinović-Duletić, Antica ; Petričević-Sinčić, Jasminka ; Čaržavec, Dubravka ; Coha, Božena ; Gverić-Krečak, Velka ; Čorović, Elizabeta ; Lang, Nada ; Lojan-Nemet, Zlatka ; Babok-Flegarić, Renata.
Izvornik
Liječnički Vjesnik (0024-3477) 132
(2010), 11-12;
333-339
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
esenacijalna trombocitemija; smjernice; Krohem
(essential thrombocythaemia; guidelines; Krohem)
Sažetak
Essential thrombocythemia (ET) is a clonal myeloproliferative neoplasm. Croatian Cooperative Group for hematologic disorders, KROHEM proposes the diagnostic and treatment guidelines for ET. Diagnosis of ET is based on the criteria and classification of World Health Organization (WHO). The level of treatment recommendation is based on the UpToDate (web based medical community database) criteria. For ET diagnosis it is mandatory to show sustained increased number of platelets with typical histomorphological changes of megakaryopoiesis in bone marrow. Secondary thrombocytosis and other chronic myeloproliferative neoplasms have to be excluded. Therapy is based on risk factors for ET. The risk factors are number of platelets, patient's age, and the risk levels for thrombosis and bleeding. Patients with low risk (age < 60 years and platelets < 1000 x 10(9)/L) arw not candidates for therapy. In younger group of patients with platelets between 1000 and 1500 x 10(9)/L or more than 1500 x 10(9)/L treatment with anagrelide or hydroxyurea is recommended respectively. In high risk patients hydroxyurea is the first line treatment. Anagrelide is indicated in these patients in the absence of treatment response. Alpha-interferon is recommended for pregnant women with ET and high platelet counts.
Izvorni jezik
Hrvatski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1980955-3094 - Genetika i funkcija hematopoeze i mikrookoliša Ph- mijeloproliferativnih bolesti (Kušec, Rajko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Opća bolnica "Dr. Josip Benčević",
Klinička bolnica "Dubrava"
Profili:
Rajko Kušec
(autor)
Boris Labar
(autor)
Božena Coha
(autor)
Branimir Jakšić
(autor)
Nada Lang
(autor)
Velka Gverić-Krečak
(autor)
Ljubica Škare-Librenjak
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- MEDLINE